Get the Stockscreener App
2.00
10.19%
0.185
After Hours:
1.94
-0.06
-3.00%
Windtree Therapeutics Inc stock is traded at $2.00, with a volume of 203.75K.
It is up +10.19% in the last 24 hours and up +1,150% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$1.815
Open:
$1.78
24h Volume:
203.75K
Relative Volume:
0.03
Market Cap:
$1.50M
Revenue:
-
Net Income/Loss:
$-11.38M
P/E Ratio:
-0.0721
EPS:
-27.73
Net Cash Flow:
$-12.72M
1W Performance:
-11.11%
1M Performance:
+1,150%
6M Performance:
-34.43%
1Y Performance:
+395.05%
1-Day Range:
$1.78
$2.20
1-Week Range:
$1.78
$2.283
52-Week Range:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
2.00 | 1.50M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
FY2024 Earnings Forecast for WINT Issued By Zacks Small Cap - Defense World
Windtree Therapeutics Secures Patent for Istaroxime IV Formulation in Acute Heart Failure - MSN
Windtree (WINT) Sees Pre-Market Surge Following Key Patent Milestone - Stocks Telegraph
SponsoredImpartialComprehensive - Research Tree
Windtree Therapeutics (WINT) Shares Are Volatile: What's Going On? - Benzinga
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage - Yahoo Finance
WINTWindtree Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Windtree's Heart Failure Treatment Gains Critical Patent ProtectionWhat This Means for AHF Patients - StockTitan
Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment - MSN
Discovery Laboratories Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015 - Marketscreener.com
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Drop in Short Interest - Defense World
Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India - The Manila Times
Windtree's Cardiac Drug Patent Filing Targets India's Massive MarketPhase 3 Trials on Horizon - StockTitan
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Windtree Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Windtree Therapeutics approves 1-for-50 reverse stock split - MSN
Windtree Therapeutics Approves 1-for-50 Reverse Stock Split; Shares Fall Pre-Bell -February 18, 2025 at 09:35 am EST - Marketscreener.com
Windtree Therapeutics Announces Reverse Stock Split Approval - TipRanks
Windtree Therapeutics approves 1-for-50 reverse stock split By Investing.com - Investing.com South Africa
Strategic 1:50 Reverse Split: Windtree's Bold Move to Secure Nasdaq Future - StockTitan
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime - MSN
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest - Defense World
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Windtree reports positive Phase 2b study on heart failure therapy By Investing.com - Investing.com South Africa
Windtree Announces Special Late-Breaking Clinical Science - GlobeNewswire
Breakthrough Heart Failure Drug Shows Remarkable Safety Profile in Latest Clinical Trial - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
The -95.92% Simple Moving Average of Windtree Therapeutics Inc’s (WINT) Stock in the Past 200 Days - The News Heater
Market Watch Highlights: Windtree Therapeutics Inc (WINT) Ends on an Downturn Note at 0.12 - The Dwinnex
Windtree Therapeutics Inc (NASDAQ: WINT) Stock Dropped -60.95% Over A Month – Any Room To Run? - Marketing Sentinel
Windtree Therapeutics enacts reverse stock split, expands equity plan - MSN
WINT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
WINT (Windtree Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
It makes sense and dollars to buy Windtree Therapeutics Inc (WINT) stock - SETE News
Windtree Therapeutics enacts reverse stock split, expands equity plan By Investing.com - Investing.com Australia
This morning’s top pick is Windtree Therapeutics Inc (NASDAQ:WINT) - US Post News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4% - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms - MSN
What Did We Find About Insider Trading At Windtree Therapeutics Inc (NASDAQ: WINT)? - Stocks Register
Windtree Therapeutics Announces Offer to Reduce Conversion Price of Series C Preferred Stock - Defense World
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
2.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):